Both histone deacetylases (HDACs) and bromodomain-containing protein 4 (BRD4) are validated as therapeutic targets in KSHV associated lymphomas, strongly supported by the excellent anticancer activity of specific inhibitors for these specialized lymphomas in vitro and in vivo [10,11]. The gene discussed is BRD4; the disease is lymphoma.